# Biologic Excipient Market > Biological Excipient Market Research Report By Source (Animal-Derived, Human-Derived, Recombinant), By Form (Liquid, Powder, Gel), By Function (Stabilizer, Emulsifier, Preservative), By End-Use Application (Vaccines, Protein Therapeutics, Monoclonal Antibodies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 15.92% - **2024:** $ 10.27 Billion - **2025:** $ 11.9 Billion - **2035:** $ 52.13 Billion - **Key Players:** BASF SE (DE), Evonik Industries AG (DE), Fujifilm Diosynth Biotechnologies (JP), Merck KGaA (DE), SABIC (SA), Lonza Group AG (CH), Cargill, Incorporated (US), Wacker Chemie AG (DE), Hyaluronic Acid (US) **Report ID:** MRFR/HC/29395-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/biologic-excipient-market-31165 --- ## Market Summary ## **Biologic Excipient Market Overview:** As per MRFR analysis, the Biologic Excipient Market Size was estimated at 10.27 (USD Billion) in 2024. The Biologic Excipient Market Industry is expected to grow from 11.90 (USD Billion) in 2025 to 44.97 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 15.92% during the forecast period (2025 - 2034). ## **Key Biologic Excipient Market Trends Highlighted** Advancements in biopharmaceutical engineering techniques have led to an increasing demand for biologics, such as monoclonal antibodies, vaccines, and therapeutic proteins. Biologic excipients play a crucial role in stabilizing biologics during formulation, storage, and delivery. The rising prevalence of chronic diseases and the increasing demand for personalized medicine are key drivers of the biological excipient market. Recent trends in the market include a growing focus on biocompatibility, sustainability, and cost-effectiveness of biologic excipients. There is a shift towards using plant-based and animal-free excipients to meet the increasing demand for vegan and cruelty-free products. Additionally, the development of novel excipients with enhanced functionalities, such as extended-release and targeted delivery, is creating new opportunities for market growth. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Biologic Excipient Market Drivers** ### **Rising Demand for Biologics** The increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and diabetes, has led to a growing demand for biologics. Biologics are complex molecules derived from living organisms that have therapeutic properties. They are used to treat a wide range of diseases, including cancer, rheumatoid arthritis, and Crohn's disease. The increasing adoption of biologics is expected to drive the growth of the biologic excipient market over the forecast period. The development of new biologics and the expansion of existing biologics into new therapeutic areas are also contributing to the growth of the market. For instance, the approval of new cancer immunotherapies and the expansion of biologics for the treatment of autoimmune diseases are expected to drive the demand for biologic excipients. Additionally, the increasing use of biologics in combination therapies is further boosting market growth. The growing adoption of biologics in emerging markets is another key factor driving the growth of the biologic excipient market. Emerging markets, such as China and India, represent a significant growth opportunity for the market. The increasing healthcare expenditure and the rising prevalence of chronic diseases in these regions are expected to drive the demand for biologics and, consequently, the demand for biologic excipients. ### **Technological Advancements in Biologic Excipient Development** The development of new and innovative excipients is essential for the advancement of the biologics industry. Biologic excipients play a critical role in ensuring the stability, efficacy, and safety of biologics. Technological advancements in excipient development have led to the development of excipients that are more effective, more stable, and more compatible with biologics. For instance, the development of novel excipients that can improve the solubility and stability of biologics has enabled the development of new and more effective biologics. Additionally, the development of excipients that can target specific delivery mechanisms has improved the efficacy of biologics. The increasing focus on patient-centric drug development is also driving the demand for excipients that can improve the safety and tolerability of biologics. Ongoing research and development in the field of biologic excipients are expected to further drive the growth of the biologic excipient market. The development of new excipients with improved properties and functionalities is expected to support the development of new and more effective biologics, thereby driving the growth of the market. ### **Supportive Government Policies and Regulatory Landscape** Government policies and regulations play a significant role in shaping the growth of the biological excipient market. Supportive government policies and a favorable regulatory landscape can encourage investment in research and development and promote the adoption of biologics and biologic excipients. For instance, the increasing focus on biosimilars and the development of biosimilar pathways in various countries is expected to drive the growth of the biologic excipient market. Biosimilars are similar to biologics but are developed and manufactured by different companies. The development of biosimilars has increased the availability and affordability of biologics, thereby driving the demand for biologic excipients. Additionally, government initiatives to support the development and manufacturing of biologics in emerging markets are expected to further drive the growth of the biologic excipient market. The increasing focus on healthcare infrastructure development and the growing awareness of biologics in emerging markets are expected to create favorable conditions for the growth of the market. ## **Biological Excipient Market Segment Insights:** ### **Biological Excipient Market Source Insights** The Biological Excipient Market is witnessing substantial growth, driven by increasing demand for biopharmaceuticals and biologics across various healthcare applications. The segmentation revealed valuable insights into the prominence of different categories, such as Animal-Derived, Human-Derived, and Recombinant excipients. Among these, the Animal-Derived segment shined with a valuation of 2.54 USD Billion, which is expected to grow to 9.67 USD Billion by 2032, reflecting its majority holding in the market. This segment's dominance was attributed to the widespread application of animal-derived components in therapeutic formulations, enhancing the biological activity necessary for effective drug delivery systems. Meanwhile, the Human-Derived category represented a robust segment valued at 3.02 USD Billion in 2023 and projected to reach 11.73 USD Billion by 2032. This segment's significance lies in its potential for high safety profiles and compatibility in clinical settings, making it a preferred choice for many pharmaceutical developers. Lastly, the Recombinant segment, valued at 2.07 USD Billion in 2023 and expected to grow to 7.39 USD Billion by 2032, also played a critical role in the market. Recombinant excipients are generating traction due to their ability to be genetically engineered and produced in a controlled manner, reducing variability and enhancing product consistency. Each of these segments contributes uniquely to the overall landscape of the Biological Excipient Market, offering diverse applications and growth opportunities driven by technological advancements, regulatory support, and the rising prevalence of chronic diseases. The growth drivers within this market are pushing for increased innovation in excipient development, with a keen focus on sourcing from these specific categories to meet the evolving needs of biopharmaceutical products. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Biological Excipient Market Form Insights** The segment encompasses various forms, including Liquid, Powder, and Gel, each playing a crucial role in the industry. Liquids are often favored for their ease of use and rapid absorption, making them vital in formulations where immediate bioavailability is essential. Powders, on the other hand, dominate due to their versatility and stability, catering to both pharmaceutical and biopharmaceutical applications. Gels also hold a noteworthy position, especially in topical formulations, where they enhance user experience and drug delivery efficacy. Overall, the Biological Excipient Market revenue is driven by increasing demand for biopharmaceuticals, advancements in drug development, and the need for innovative excipients. These trends collectively shape the market growth, making it essential for stakeholders to navigate the evolving landscape effectively. The Biological Excipient Market statistics illustrate the growing relevance of each form while highlighting opportunities and challenges in this dynamic industry. ### **Biological Excipient Market Function Insights** The Biological Excipient Market showcases a diverse Function segmentation that plays a crucial role in the efficacy and stability of biological products. This segment includes vital components such as Stabilizers, Emulsifiers, and Preservatives, each contributing significantly to the overall market dynamics. Stabilizers are essential for maintaining the physical and chemical integrity of formulations, which supports the growing demand for stable biological products. Emulsifiers facilitate the mixing of hydrophilic and hydrophobic components, ensuring uniformity in formulations, which is increasingly important in various applications. Preservatives, meanwhile, are critical for extending the shelf life of biological products by preventing microbial growth, thereby enhancing safety and efficacy. The Biological Excipient Market data reflects a steady trend toward biopharmaceutical formulations that require these functional ingredients, highlighting their importance. As the industry progresses, challenges such as regulatory dynamics and sourcing natural excipients remain, yet they also present opportunities for innovation and growth within the Biological Excipient Market. Key trends indicate a heightened focus on sustainable and efficient excipients, suggesting a shift in consumer preferences that could drive market growth in the coming years. ### **Biological Excipient Market End-Use Application Insights** The Biological Excipient Market showcases significant growth potential primarily driven by its various End-Use Applications, notably in Vaccines, Protein Therapeutics, and Monoclonal Antibodies. This segment plays a crucial role in enhancing the efficacy and stability of biopharmaceuticals, reflecting the increasing demand for safe and effective therapeutic solutions. Vaccines, as a predominant segment, facilitate the delivery of immunogenic components, thereby promoting health initiatives. Protein Therapeutics benefit from biological excipients through improved solubility and shelf life, which is vital for the management of chronic diseases. Moreover, Monoclonal Antibodies represent a significant portion of the market due to their targeted therapeutic capabilities in treating various conditions, including cancers and autoimmune disorders. The increasing prevalence of these diseases, along with advancements in biopharmaceutical innovations, propels the demand for effective biological excipients. As the market expands, it presents various opportunities for stakeholders to meet the rising needs in healthcare, while understanding market trends is essential for navigating growth drivers and challenges within the Biological Excipient Market. ### **Biological Excipient Market Regional Insights** The Biological Excipient Market is poised for substantial growth across various regions, reflecting diverse demands and developments. In North America, the market held a significant valuation of 3.25 USD Billion in 2023, which is expected to grow to 12.57 USD Billion by 2032, making it a dominant player due to advanced healthcare infrastructure and high pharmaceutical expenditure. Europe followed with a valuation of 2.35 USD Billion in 2023, reaching 9.05 USD Billion in 2032, driven by increased research and development activities. The Asia Pacific region, valued at 1.85 USD Billion in 2023, is forecasted to expand to 7.27 USD Billion, highlighting its potential as a growing market due to rising healthcare access and manufacturing capabilities. South America, though smaller, reached 0.65 USD Billion in 2023, projected to grow to 2.57 USD Billion as economies in the region are rapidly developing. Lastly, the Middle East and Africa segment, valued at 0.53 USD Billion in 2023, with expectations of reaching 1.33 USD Billion, was gaining traction through improving healthcare markets and increasing investments. The market growth can be attributed to factors such as the rising prevalence of diseases and an increasing focus on biopharmaceuticals, creating opportunities for innovation and expansion in the Biological Excipient Market revenue. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Biologic Excipient Market Key Players And Competitive Insights:** Major players in the Biologic Excipient Market are constantly developing and enhancing their product offerings to meet the evolving needs of the market. Leading Biologic Excipient Market players are focusing on research and development to introduce innovative and advanced biologic excipients. The Biologic Excipient Market development is driven by increasing demand for biologics and [biopharmaceuticals](../../../reports/biopharmaceuticals-market-8439), growing adoption of biologics in various therapeutic areas, and supportive government regulations. The Biologic Excipient Market Competitive Landscape is characterized by a mix of established players and emerging companies. Pfizer is a leading player in the Biologic Excipient Market and a pharmaceutical company. They offer a range of biologic excipients, including cell culture media, serum-free media, and protein purification reagents. Pfizer has a strong focus on research and development and is committed to providing innovative and high-quality products to its customers. Samsung Biologics is a leading competitor in the Biologic Excipient Market and a contract development and manufacturing organization. They provide a range of biologic excipient services, including cell line development, bioprocess optimization, and fill and finish. Samsung Biologics has a strong track record of success and is known for its high-quality products and services. **Key Companies in the Biologic Excipient Market Include:** ## **Biologic Excipient Market Developments** The market growth is attributed to rising demand for biologics, increasing prevalence of chronic diseases, and technological advancements in the pharmaceutical industry. Key industry developments include: In 2023, Lonza announced the expansion of its biologics excipient manufacturing facility in Portsmouth, New Hampshire, to meet the growing demand for high-quality excipients. In 2022, Merck KGaA launched a new range of excipients specifically designed for biologics, offering enhanced stability and functionality. Several biopharmaceutical companies are collaborating with excipient manufacturers to develop innovative excipients that address specific challenges in biologic drug development and manufacturing. ## **Biologic Excipient Market Segmentation Insights** ## Market Drivers ### Stringent Regulatory Frameworks The Biologic Excipient Market is shaped by stringent regulatory frameworks that govern the development and approval of biologics. Regulatory agencies are increasingly emphasizing the quality and safety of excipients used in biologic formulations. This heightened scrutiny is likely to drive manufacturers to invest in high-quality excipients that comply with regulatory standards. In 2025, the market for regulatory-compliant excipients is expected to grow, reflecting the industry's commitment to safety and efficacy. As companies navigate these regulations, the demand for biologic excipients that meet rigorous quality standards will likely increase, thereby influencing market dynamics. This trend underscores the importance of regulatory compliance in shaping the future of the biologic excipient market. ### Increasing Investment in Biologics The Biologic Excipient Market is experiencing a surge in investment as pharmaceutical companies recognize the potential of biologics. This trend is driven by the increasing prevalence of chronic diseases and the need for innovative therapies. In 2025, the market for biologics is projected to reach approximately 300 billion USD, indicating a robust growth trajectory. As companies allocate more resources towards research and development, the demand for biologic excipients is likely to rise. These excipients play a crucial role in enhancing the stability and efficacy of biologic formulations, thereby attracting significant attention from investors. The influx of capital is expected to foster innovation and expand the range of available biologic excipients, ultimately benefiting the market. ### Growing Focus on Sustainable Practices The Biologic Excipient Market is increasingly influenced by a growing focus on sustainability. As environmental concerns gain prominence, pharmaceutical companies are seeking excipients that are derived from renewable sources and have a lower environmental impact. This shift towards sustainable practices is likely to drive innovation in the development of biologic excipients. In 2025, the market for sustainable excipients is projected to expand significantly, reflecting the industry's response to consumer demand for environmentally friendly products. Manufacturers are encouraged to explore biodegradable and eco-friendly excipients, which could enhance their competitive edge in the biologic excipient market. This trend not only aligns with global sustainability goals but also presents new opportunities for growth within the industry. ### Rising Demand for Personalized Medicine The Biologic Excipient Market is witnessing a notable shift towards personalized medicine, which is reshaping the landscape of drug development. As healthcare providers increasingly focus on tailoring treatments to individual patient needs, the demand for biologics that utilize specific excipients is likely to grow. This trend is supported by the fact that personalized therapies often require unique formulations, which depend heavily on the choice of excipients. In 2025, the market for personalized medicine is anticipated to exceed 100 billion USD, further driving the need for specialized biologic excipients. Consequently, manufacturers are compelled to innovate and develop excipients that can accommodate the complexities of personalized therapies, thereby enhancing their market position. ### Advancements in Formulation Technologies The Biologic Excipient Market is significantly influenced by advancements in formulation technologies. Innovations such as nanotechnology and microencapsulation are enabling the development of more effective biologic products. These technologies enhance the delivery and stability of biologics, which is crucial for their therapeutic effectiveness. As a result, the demand for biologic excipients that can support these advanced formulations is expected to increase. In 2025, the market for advanced drug delivery systems is projected to reach around 50 billion USD, indicating a strong correlation between technological advancements and the growth of the biologic excipient market. This dynamic environment encourages manufacturers to invest in research and development to create excipients that meet the evolving needs of the industry. ## Future Outlook The Biologic Excipient Market is projected to grow at a 15.92% CAGR from 2025 to 2035, driven by increasing demand for biologics and advancements in formulation technologies. **New opportunities:** - Development of novel biologic excipients for enhanced stability and delivery. - Strategic partnerships with biopharmaceutical companies for co-development initiatives. - Expansion into emerging markets with tailored excipient solutions. By 2035, the Biologic Excipient Market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Source: Animal-Derived (Largest) vs. Recombinant (Fastest-Growing) In the Biologic Excipient Market, the source segment showcases a diverse landscape with Animal-Derived excipients holding the largest market share. These excipients have established a strong presence in various applications, owing to their effectiveness in enhancing drug formulation and stability. The Human-Derived excipients also contribute substantially, reflecting their significance in biologics, but they lag behind the Animal-Derived category in terms of market dominance. The Recombinant segment is emerging rapidly as the fastest-growing source in the market. This growth can be attributed to advancements in biotechnology that enable consistent production and modification of excipients. The shift towards safer and more sustainable alternatives has further propelled recombinant excipients, as they minimize the risk of disease transmission associated with animal-derived materials while meeting the increasing demand for innovative drug delivery solutions. Animal-Derived (Dominant) vs. Recombinant (Emerging) Animal-Derived excipients are currently the dominant players in the Biologic Excipient Market, owing to their proven efficacy and historical use in pharmaceutical products. They offer a variety of benefits, such as improved solubility and stability for biologics. However, the trend is shifting toward Recombinant excipients, which are gaining traction as an emerging alternative. Recombinant excipients are produced through biotechnological methods, providing enhanced purity and consistency compared to traditional animal-derived options. As regulatory scrutiny around safety increases, the appeal for recombinant products grows, attracting manufacturers looking for compliant and innovative solutions. The competition between these two sources highlights a critical evolution in the market, focusing on safety, sustainability, and therapeutic effectiveness. ### By Form: Liquid (Largest) vs. Powder (Fastest-Growing) In the Biologic Excipient Market, the form segment exhibits a distinct distribution characterized by Liquid, Powder, and Gel categories. Liquid excipients are prevalent, accounting for a significant share of the market due to their versatility and compatibility with various biological formulations. On the other hand, Powder excipients are gaining traction, reflecting a growing preference for solid formulations that offer stabilization benefits and ease of transportation. Gel excipients, while currently sharing a smaller market presence, are carving out a niche in specific applications such as topical therapies and controlled release systems. Liquid (Dominant) vs. Powder (Emerging) Liquid excipients dominate the Biologic Excipient Market due to their extensive application across diverse formulations, offering advantages such as ease of incorporation, enhanced solubility, and patient compliance. They are favored in injectables and reconstitutable formulations, ensuring effective delivery of biologics. Conversely, Powder excipients are emerging as a key player as they provide excellent stability and shelf-life extension, making them suitable for lyophilized products and oral dosage forms. Their growth is driven by rising demand for solid forms that simplify manufacturing and improve drug delivery systems. The evolving trend towards powder form encapsulations is fueling innovation in excipient technology, enhancing their appeal in the biologics landscape. ### By Function: Stabilizer (Largest) vs. Emulsifier (Fastest-Growing) In the Biologic Excipient Market, the function segment is primarily driven by stabilizers, which hold the largest share due to their critical role in maintaining the integrity and efficacy of biologic products. Emulsifiers are also prominent but are recognized for their growth potential, reflecting a dynamic shift in formulation strategies. Together, these functional excipients cater to the complex requirements of therapeutic agents, ensuring product stability and bioavailability in delivery systems. As the Biologic Excipient Market expands, the demand for specialized stabilizers is being fueled by the increasing complexity of biologics, including monoclonal antibodies and gene therapies. Furthermore, emulsifiers are gaining traction as formulators seek innovative solutions to enhance product performance and stability. The growing focus on optimizing bioavailability and patient compliance further complements the upward trajectory of this segment, indicating a promising outlook fueled by continuous advancements in excipient technology. Stabilizer (Dominant) vs. Emulsifier (Emerging) Stabilizers are essential in the Biologic Excipient Market, providing a robust foundation for drug formulations by minimizing degradation and maintaining consistency in efficacy. Their dominance stems from the increasing reliance on biologics that require specific conditions to remain stable during production and storage, thus ensuring safety and effectiveness. In contrast, emulsifiers are emerging as a vital component, particularly in the formulation of complex drugs that require a stable mixture of oil and water phases. They enhance the product's stability and consistency, making them indispensable in developing innovative delivery systems. As the focus on biologic therapies intensifies, both stabilizers and emulsifiers will continue to play crucial roles in driving advancements in formulation technology. ### By End-Use Application: Vaccines (Largest) vs. Monoclonal Antibodies (Fastest-Growing) The Biologic Excipient Market is primarily segmented into three main applications: Vaccines, Protein Therapeutics, and Monoclonal Antibodies. Among these, Vaccines hold the largest share as they are essential for public health and have seen consistent demand due to ongoing vaccination campaigns worldwide. At the same time, Monoclonal Antibodies are emerging swiftly, benefiting from the growing focus on targeted therapies that promise improved efficacy and safety, thus driving their market share upwards. Vaccines: Dominant vs. Monoclonal Antibodies: Emerging Vaccines are the dominant application, extensively used in immunization processes and supported by governmental health initiatives. Their requirement for high safety and stability standards in biologic excipients drives innovation in excipient formulations. On the other hand, Monoclonal Antibodies, as an emerging segment, are gaining attention due to their effectiveness in treating chronic diseases, including various cancers and autoimmune disorders. The increasing prevalence of these conditions, along with significant investment in research and development, is accelerating the growth of this segment, highlighting a shift in focus toward personalized medicine. ## Regional Market Share Analysis ### North America : Innovation and Market Leadership North America is the largest market for biologic excipients, holding approximately 45% of the global share. The region benefits from a robust pharmaceutical industry, significant R&D investments, and favorable regulatory frameworks that encourage innovation. The increasing demand for biologics and biopharmaceuticals is driving growth, with a focus on advanced excipients that enhance drug delivery and stability. Regulatory bodies like the FDA are actively promoting guidelines that support the development of biologic products. The United States is the leading country in this market, followed by Canada. Major players such as BASF SE, Merck KGaA, and Cargill, Incorporated are headquartered here, contributing to a competitive landscape characterized by continuous innovation and strategic partnerships. The presence of advanced manufacturing facilities and research institutions further strengthens the market position of North America in the biologic excipient sector. ### Europe : Regulatory Framework and Growth Europe is the second-largest market for biologic excipients, accounting for approximately 30% of the global market share. The region is characterized by stringent regulatory standards and a strong emphasis on quality and safety in pharmaceutical products. The European Medicines Agency (EMA) plays a crucial role in shaping regulations that facilitate the development of biologics, thereby driving demand for innovative excipients. The increasing prevalence of chronic diseases is also propelling market growth as more biologics are developed to address these health challenges. Germany, France, and the UK are the leading countries in this market, with Germany being the largest contributor. Key players like Evonik Industries AG and Merck KGaA are prominent in the region, focusing on developing high-quality excipients that meet regulatory requirements. The competitive landscape is marked by collaborations between pharmaceutical companies and excipient manufacturers, enhancing innovation and market reach. ### Asia-Pacific : Emerging Market Potential Asia-Pacific is an emerging powerhouse in the biologic excipient market, holding approximately 20% of the global share. The region is witnessing rapid growth driven by increasing investments in biotechnology and pharmaceuticals, along with a rising demand for biologics. Countries like China and India are at the forefront, supported by government initiatives aimed at boosting the biopharmaceutical sector. Regulatory bodies are also evolving to accommodate the unique needs of biologic products, further catalyzing market expansion. China is the largest market in the region, followed by India and Japan. The competitive landscape is becoming increasingly dynamic, with both local and international players vying for market share. Companies like Fujifilm Diosynth Biotechnologies and Lonza Group AG are expanding their operations in the region, focusing on innovative excipients that enhance drug efficacy and safety. The growing emphasis on research and development is expected to further propel the market in Asia-Pacific. ### Middle East and Africa : Resource-Rich and Growing Demand The Middle East and Africa (MEA) region is gradually emerging in the biologic excipient market, holding about 5% of the global share. The growth is primarily driven by increasing healthcare investments and a rising demand for advanced pharmaceutical products. Countries in the Gulf Cooperation Council (GCC) are particularly focusing on enhancing their healthcare infrastructure, which is expected to boost the demand for biologics and their excipients. Regulatory frameworks are also being developed to support the growth of the biopharmaceutical sector in the region. South Africa and the UAE are the leading countries in this market, with a growing number of local manufacturers entering the biologic excipient space. The competitive landscape is characterized by collaborations between international companies and local firms, aimed at leveraging regional resources and expertise. As the market matures, the presence of key players is expected to increase, further driving innovation and growth in the MEA region. ## Competitive Benchmarking Major players in the Biologic Excipient Market are constantly developing and enhancing their product offerings to meet the evolving needs of the market. Leading Biologic Excipient Market players are focusing on research and development to introduce innovative and advanced biologic excipients. The Biologic Excipient Market development is driven by increasing demand for biologics and [biopharmaceuticals](../../../reports/biopharmaceuticals-market-8439), growing adoption of biologics in various therapeutic areas, and supportive government regulations. The Biologic Excipient Market Competitive Landscape is characterized by a mix of established players and emerging companies. Pfizer is a leading player in the Biologic Excipient Market and a pharmaceutical company. They offer a range of biologic excipients, including cell culture media, serum-free media, and protein purification reagents. Pfizer has a strong focus on research and development and is committed to providing innovative and high-quality products to its customers. Samsung Biologics is a leading competitor in the Biologic Excipient Market and a contract development and manufacturing organization. They provide a range of biologic excipient services, including cell line development, bioprocess optimization, and fill and finish. Samsung Biologics has a strong track record of success and is known for its high-quality products and services. ## Recent News & Developments The market growth is attributed to rising demand for biologics, increasing prevalence of chronic diseases, and technological advancements in the pharmaceutical industry. Key industry developments include: In 2023, Lonza announced the expansion of its biologics excipient manufacturing facility in Portsmouth, New Hampshire, to meet the growing demand for high-quality excipients. In 2022, Merck KGaA launched a new range of excipients specifically designed for biologics, offering enhanced stability and functionality. Several biopharmaceutical companies are collaborating with excipient manufacturers to develop innovative excipients that address specific challenges in biologic drug development and manufacturing. ## Report Scope | MARKET SIZE 2024 | 10.27(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 11.9(USD Billion) | | MARKET SIZE 2035 | 52.13(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.92% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | BASF SE (DE), Evonik Industries AG (DE), Fujifilm Diosynth Biotechnologies (JP), Merck KGaA (DE), SABIC (SA), Lonza Group AG (CH), Cargill, Incorporated (US), Wacker Chemie AG (DE), Hyaluronic Acid (US) | | Segments Covered | Source, Form, Function, End-Use Application, Regional | | Key Market Opportunities | Advancements in biologic excipients enhance drug delivery and stability, driving innovation in the Biologic Excipient Market. | | Key Market Dynamics | Rising demand for biologic excipients driven by regulatory changes and technological advancements in drug formulation. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Biologic Excipient Market as of 2024?** A: The overall market valuation was 10.27 USD Billion in 2024. **Q: What is the projected market size for the Biologic Excipient Market in 2035?** A: The projected valuation for the Biologic Excipient Market is 52.13 USD Billion in 2035. **Q: What is the expected CAGR for the Biologic Excipient Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Biologic Excipient Market during the forecast period 2025 - 2035 is 15.92%. **Q: Which segment is projected to have the highest valuation in the Biologic Excipient Market by 2035?** A: The Recombinant segment is projected to reach 24.63 USD Billion by 2035. **Q: What are the key functions of biologic excipients in the market?** A: Key functions include Stabilizers, Emulsifiers, and Preservatives, with Preservatives projected to reach 24.18 USD Billion by 2035. **Q: Which form of biologic excipients is expected to dominate the market by 2035?** A: The Powder form is expected to dominate, with a projected valuation of 20.65 USD Billion by 2035. **Q: Who are the leading players in the Biologic Excipient Market?** A: Key players include BASF SE, Evonik Industries AG, and Merck KGaA, among others. **Q: What is the projected valuation for the Human-Derived segment by 2035?** A: The Human-Derived segment is projected to reach 15.0 USD Billion by 2035. **Q: How does the market for Monoclonal Antibodies compare to other end-use applications by 2035?** A: The Monoclonal Antibodies segment is projected to reach 18.72 USD Billion by 2035, indicating strong growth. **Q: What is the expected growth trend for the Biologic Excipient Market in the coming years?** A: The market appears to be on a robust growth trajectory, driven by increasing demand and innovation. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/biologic-excipient-market-31165*